A new international biotech group was born from the integration of Hyris Ltd. and Ulisse Biomed S.p.A. Hyris Ulisse Corporate Integration: A new benchmark in the biotech market. As anticipated on December 4th, the integration between Hyris and Ulisse Biomed was officially ratified on December 21st by completing a reverse take-over operation and following the shareholders' meeting of Ulisse Biomed held earlier on that same day, which also deliberated an increase of capital in option. The overarching goal is to give life to a new Italian segment of excellence in genetic analysis based on strong innovation competencies and ready to address international markets at scale.

The new Group, with strong roots in diagnostics, teranosis and healthcare, aims to create a strong actor operating as a leader in the in-vitro diagnostics industry, particularly molecular biology, thanks to flawless interoperability between its leading technologies. The new structure aims to provide an integrated array of high-end performance products at a competitive cost to meet a diverse industry demand across various markets, defining a new portfolio of distinctive analytical capabilities at a global level.